



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Report for the Application Evaluation Assessment Part I

A double-blind, randomized, placebo-controlled trial to test the efficacy, safety and tolerability of Dimethyl Fumarate in Friedreich Ataxia (DMF-FA-201).

2022-503016-16-00

Assessment Part I	
Conclusion	
<b>Conclusion reporting date:</b>  28/04/2023  <b>Final conclusion:</b>  Acceptable with conditions	
Condition:	
<b>Number:</b>  1  <b>Condition:</b>  The study is approved with the condition of providing the Investigators with the list of acronyms and adding it in the context of the next protocol amendment	